Highlights Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
2.69 ^USD	-2.89%		-4.27%	+33.17%

Jun. 06	Aquestive Therapeutics, Inc. Promotes Cassie Jung as Chief Operating Officer	CI
Jun. 03	Aquestive Therapeutics, Inc. Announces Executive Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q1 Revenue $12.1M, vs. Street Est of $12.3M	May. 07	MT
Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	May. 07	CI
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film	Apr. 29	CI
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	Apr. 12	CI
Top Midday Decliners	Mar. 20	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	Mar. 20	MT
Top Premarket Decliners	Mar. 20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	Mar. 20	MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	Mar. 19	MT
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	Mar. 14	CI
Aquestive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q4 Revenue $13.2M, vs. Street Est of $11.6M	Mar. 05	MT
Aquestive Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Mar. 05	CI
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm (epinephrine) Sublingual Film	Dec. 05	CI
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q3 Revenue $13M, vs. Street Est of $11.5M	Nov. 06	MT
Aquestive Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023	Nov. 06	CI
Aquestive Therapeutics, Inc. Provides an Update on the Development Timeline and Pathway for Its Oral Epinephrine Product Candidate, Anaphylm	23-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Highlights

Filters